Patents by Inventor Andrew R. Chadeayne
Andrew R. Chadeayne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12187680Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.Type: GrantFiled: November 21, 2023Date of Patent: January 7, 2025Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 12180157Abstract: The disclosure relates to crystalline form 1 of 5-hydroxy-N,N,N-trimethyl-tryptammonium (5-HTQ) iodide, and to pharmaceutical compositions containing the compound and to methods of treatment using it.Type: GrantFiled: January 13, 2022Date of Patent: December 31, 2024Assignee: CAAMTECH, INCInventor: Andrew R Chadeayne
-
Patent number: 12162835Abstract: The disclosure relates to crystalline psilacetin derivatives, compositions containing those crystalline derivatives, and methods of treatment using them. The crystalline psilacetin derivatives include crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate (“crystalline 4-AcO-MET hydrofumarate”), crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate (“crystalline 4-AcO-MALT hydrofumarate”), and crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid (“crystalline 4-AcO-DALT fumarate fumaric acid”).Type: GrantFiled: July 6, 2023Date of Patent: December 10, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 12134598Abstract: The disclosure relates to crystalline form 1 of [2-(5-methoxy-1H-indol-3-yl)ethyl]dipropylamine (5-MeO-DPT) and to crystalline form 1 of bis([2-(5-methoxy-1H-indol-3-yl)ethyl]dipropylazanium) (2E)-but-2-enedioate (5-MeO-DPT fumarate), and to pharmaceutical compositions containing the compounds and methods of treatment using them.Type: GrantFiled: January 25, 2022Date of Patent: November 5, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R Chadeayne
-
Patent number: 12077499Abstract: The disclosure relates to crystalline forms of bis(4-hydroxy-N-methyl-N-isopropyltryptammonium) fumarate (“crystalline bis-miprocin fumarate”), compositions containing that crystalline form, and their methods of treatment using them.Type: GrantFiled: May 15, 2023Date of Patent: September 3, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 12017991Abstract: The disclosure relates to compounds of formula (I): Among the substituents in a compound of formula (I), one of R4 and R5 is hydrogen and the other of R4 and R5 is —OSC2Rs6. The disclosure relates to compounds of formula (II): Among the substituents in a compound of formula (II), R6 is a halogen chosen from F, Cl, Br, and I. The disclosure relates to compositions comprising a compound of formulas (I) or (II) and an excipient. The disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I) or (II). The disclosure relates to therapeutic uses of compounds of formulas (I) or (II).Type: GrantFiled: January 10, 2022Date of Patent: June 25, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R Chadeayne
-
Patent number: 12006290Abstract: The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.Type: GrantFiled: March 18, 2021Date of Patent: June 11, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11981637Abstract: The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.Type: GrantFiled: October 31, 2022Date of Patent: May 14, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11974984Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.Type: GrantFiled: November 11, 2020Date of Patent: May 7, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11926590Abstract: This disclosure relates to crystalline bis(4-hydroxy-N,N-d-n-propyltryptammonium)fumarate tetrahydrate (4-HO-DPT fumarate-4H2O) and to Crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions containing crystalline 4-HO-DPT fumarate-4H2O or crystalline 4-HO-DPT chloride, and methods of use are disclosed.Type: GrantFiled: May 19, 2021Date of Patent: March 12, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11884625Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.Type: GrantFiled: May 13, 2022Date of Patent: January 30, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11858896Abstract: The disclosure relates to N-methyl-N-allyl-tryptamine (MALT) hydrofumarate, crystalline MALT hydrofumarate, N—N-dibutyl-tryptamine (DBT) iodide, crystalline DBT iodide, crystalline N-ethyl-N-propyl-tryptamine (EPT) hydrofumarate, and crystalline N—N-diisopropyl-tryptamine (DiPT) hydrofumarate, compositions containing them, and the methods of treatment using them.Type: GrantFiled: May 4, 2021Date of Patent: January 2, 2024Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11819475Abstract: Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.Type: GrantFiled: July 29, 2021Date of Patent: November 21, 2023Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11780808Abstract: The disclosure relates to crystalline forms of bis(4-hydroxy-N-methyl-N-isopropyltryptammonium) fumarate (“crystalline bis-miprocin fumarate”), compositions containing that crystalline form, and their methods of treatment using them.Type: GrantFiled: February 26, 2021Date of Patent: October 10, 2023Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11753375Abstract: The disclosure relates to crystalline psilacetin derivatives, compositions containing those crystalline derivatives, and methods of treatment using them. The crystalline psilacetin derivatives include crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate (“crystalline 4-AcO-MET hy-drofumarate”), crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate (“crystalline 4-AcO-MALT hydrofumarate”), and crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid (“crystalline 4-AcO-DALT fumarate fumaric acid”).Type: GrantFiled: March 18, 2021Date of Patent: September 12, 2023Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11739060Abstract: The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.Type: GrantFiled: April 6, 2021Date of Patent: August 29, 2023Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11471439Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.Type: GrantFiled: July 29, 2021Date of Patent: October 18, 2022Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11358934Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.Type: GrantFiled: March 23, 2020Date of Patent: June 14, 2022Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 11332441Abstract: Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate).Type: GrantFiled: March 23, 2020Date of Patent: May 17, 2022Assignee: CAAMTECH, INC.Inventor: Andrew R. Chadeayne
-
Patent number: 10933073Abstract: This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.Type: GrantFiled: February 9, 2018Date of Patent: March 2, 2021Assignee: CAAMTECH LLCInventor: Andrew R. Chadeayne